Structure Therapeutics reported Phase 2 efficacy and tolerability data for its oral GLP-1 candidate aleniglipron showing pronounced weight loss and improved retention. In a trial of 61 treated patients, step-up dosing to 120 mg and higher produced up to ~15% body-weight reduction at 44 weeks; the company later highlighted a 16% placebo-adjusted result in broader reporting. Structure attributed fewer discontinuations to a slower dose escalation strategy. Analysts quoted in company coverage called the results competitive with upcoming oral entrants from Eli Lilly and Novo Nordisk and said the pill could pressure market dynamics for oral versus injectable GLP-1s. The data now set the stage for a Phase 3 push amid intensifying regulatory and commercial competition for oral obesity therapies.